Clarius Group LLC increased its position in shares of Stryker Corporation (NYSE:SYK – Free Report) by 4.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,111 shares of the medical technology company’s stock after acquiring an additional 84 shares during the quarter. Clarius Group LLC’s holdings in Stryker were worth $835,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also bought and sold shares of SYK. Consolidated Portfolio Review Corp boosted its holdings in shares of Stryker by 4.2% in the second quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company’s stock valued at $256,000 after buying an additional 26 shares during the period. Sunflower Bank N.A. boosted its holdings in shares of Stryker by 4.0% in the second quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock valued at $275,000 after buying an additional 27 shares during the period. Pitti Group Wealth Management LLC boosted its holdings in shares of Stryker by 3.2% in the second quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock valued at $341,000 after buying an additional 27 shares during the period. Continuum Advisory LLC boosted its holdings in shares of Stryker by 5.8% in the first quarter. Continuum Advisory LLC now owns 532 shares of the medical technology company’s stock valued at $198,000 after buying an additional 29 shares during the period. Finally, Oakworth Capital Inc. boosted its holdings in shares of Stryker by 0.5% in the first quarter. Oakworth Capital Inc. now owns 6,133 shares of the medical technology company’s stock valued at $2,283,000 after buying an additional 29 shares during the period. Institutional investors own 77.09% of the company’s stock.
Insiders Place Their Bets
In related news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Viju Menon sold 500 shares of the business’s stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on Stryker
Stryker Price Performance
Shares of SYK opened at $370.59 on Monday. The company has a market cap of $141.68 billion, a price-to-earnings ratio of 49.08, a PEG ratio of 2.67 and a beta of 0.94. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19. The company’s fifty day simple moving average is $382.81 and its 200 day simple moving average is $378.96. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70.
Stryker (NYSE:SYK – Get Free Report) last issued its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping analysts’ consensus estimates of $3.07 by $0.06. The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.
Stryker Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s payout ratio is presently 44.50%.
Stryker Profile
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Further Reading
- Five stocks we like better than Stryker
- Investing In Automotive Stocks
- 3 Defense Stocks Surging as Ukraine Tensions Deepen
- What Makes a Stock a Good Dividend Stock?
- Starbucks Stock Slumps; This Competitor Shows Strength
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.